143 related articles for article (PubMed ID: 12667341)
1. [Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma].
Ma S; Sheng X; Luo R; Li A
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):619-20. PubMed ID: 12667341
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Di Renzo N; Brugiatelli M; Montanini A; Vigliotti ML; Cervetti G; Liberati AM; Luminari S; Spedini P; Giglio G; Federico M
Leuk Lymphoma; 2006 Mar; 47(3):473-9. PubMed ID: 16396771
[TBL] [Abstract][Full Text] [Related]
4. Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.
el Aziz LM
Med Oncol; 2014 Nov; 31(11):244. PubMed ID: 25294423
[TBL] [Abstract][Full Text] [Related]
5. Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.
Zhong DT; Shi CM; Chen Q; Huang JZ; Liang JG
Ann Hematol; 2012 Nov; 91(11):1757-63. PubMed ID: 22790106
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma.
Yang SH; Lin ZZ; Kuo SH; Cheng AL
Am J Hematol; 2009 Jul; 84(7):457-9. PubMed ID: 19484737
[No Abstract] [Full Text] [Related]
9. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.
Fosså A; Santoro A; Hiddemann W; Truemper L; Niederle N; Buksmaui S; Bonadonna G; Seeber S; Nowrousian MR
J Clin Oncol; 1999 Dec; 17(12):3786-92. PubMed ID: 10577850
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M; Avigdor A; Ribakovsky E; Nagler A; Kedmi M
Acta Haematol; 2019; 141(2):84-90. PubMed ID: 30630175
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.
Kim KH; Joo YD; Sohn CH; Shin HJ; Chung JS; Cho GJ; Shin SH; Kim YS; Lee WS
Korean J Intern Med; 2009 Mar; 24(1):37-42. PubMed ID: 19270480
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Eom HS; Kim JS; Lee YY; Oh SJ; Lee DH; Suh C
Invest New Drugs; 2011 Feb; 29(1):154-60. PubMed ID: 19756371
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T
Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L
Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732
[TBL] [Abstract][Full Text] [Related]
16. Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
Jo JC; Baek JH; Lee JH; Joo YD; Bae SH; Lee JL; Lee JH; Kim DY; Lee WS; Ryoo HM; Choi Y; Kim H; Lee KH;
Asia Pac J Clin Oncol; 2016 Jun; 12(2):159-66. PubMed ID: 26956432
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
Emmanouilides C; Colovos C; Pinter-Brown L; Hernandez L; Schiller G; Territo M; Rosen P
Clin Lymphoma; 2004 Jun; 5(1):45-9. PubMed ID: 15245607
[TBL] [Abstract][Full Text] [Related]
18. The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience.
Batgi H; Merdin A; Dal MS; Kızıl Çakar M; Yıldız J; Başçı S; Uncu Ulu B; Yiğenoğlu TN; Darçın T; Şahin D; Bakırtaş M; Tetik A; İskender D; Altuntaş F
J Oncol Pharm Pract; 2020 Dec; 26(8):1857-1863. PubMed ID: 32098553
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
Müller-Beissenhirtz H; Kasper C; Nückel H; Dührsen U
Ann Hematol; 2005 Nov; 84(12):796-801. PubMed ID: 16041531
[TBL] [Abstract][Full Text] [Related]
20. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]